Through translational prospective study, the GSTP1 Ile105Val polymorphism emerges as prognostic marker in de novo large B-cell lymphoma patients

Blood Cancer J. 2017 Apr 28;7(4):e560. doi: 10.1038/bcj.2017.38.

Authors

M T Delamain¹, E C M Miranda¹, G J Lourenço², C A de Souza³, C S P Lima²

Affiliations

¹ Hematology and Hemotherapy Center, University of Campinas, Sao Paulo, Brazil.
² Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Sao Paulo, Brazil.
³ Department of Internal Medicine, Hematology and Hemotherapy Center, Faculty of Medical Sciences, University of Campinas, Sao Paulo, Brazil.

No abstract available

Publication types

Letter

MeSH terms

Amino Acid Substitution
Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Biomarkers, Tumor
Cyclophosphamide / administration & dosage
Disease-Free Survival
Doxorubicin / administration & dosage
Female
Glutathione S-Transferase pi / genetics*
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / genetics*
Lymphoma, Large B-Cell, Diffuse / mortality*
Male
Mutation, Missense*
Polymorphism, Genetic*
Prednisone / administration & dosage
Prospective Studies
Rituximab
Survival Rate
Translational Research, Biomedical
Vincristine / administration & dosage

Substances

Antibodies, Monoclonal, Murine-Derived
Biomarkers, Tumor
R-CHOP protocol
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
GSTP1 protein, human
Glutathione S-Transferase pi
Prednisone